Clearside Biomedical, Inc. (CLSD)
- GlobeNewswire
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector® - - Topline Data Expected to be Reported During the Week of October 7, 2024 - ALPHARETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced the completion of the final participant visit in the C
- Zacks
After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)
Clearside Biomedical (CLSD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 64.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
